Superior Attributes Push Preference for RNA Sequencing over Conventional Sequencing Techniques

RNA sequencing has been largely considered as a vital tool to dig deeper into the cell transcriptome for insights on differential gene expression. Over the past decade, the ubiquity of RNA sequencing technique has seen rapid increase, and the adoption remains higher owing to its superior performance than that of the conventional microarray-based techniques, and Sanger sequencing method. With broader coverage, and greater resolution capabilities, RNA sequencing will continue to represent a significantly large market. The dramatically increasing number of grants for research activities in the field of next-generation sequencing (NGS)-based RNA sequencing is expected to remain a solid booster to the growth of the global RNA sequencing market. Growing significance in cancer research, and agricultural research will continue to be an important factor driving market growth. As new exciting areas of application such as spatial transcriptomics, and precision medicine emerge on the horizon, adoption of RNA sequencing is projected to proliferate over the forecast period.

Expression Profiling Top Application Type in RNA Sequencing Market

Today, the advent of sequencing technology enables direct, long-read RNA sequencing. A range of innovative computational tools are also available to assist. These will further complement the progress of the RNA sequencing market. Driven by technological advances, and increasing availability, the demand for RNA sequencing platforms and consumables continues to generate a remarkable revenue in the market. Sequencing by synthesis, on the other hand, will most likely be the preferred technology among end users. The application is anticipated to remain maximum for expression profiling, which is attributable to the rising prevalence of metabolic disorders, an increasing number of cases of multiple sclerosis, as well as that of some other conditions. Gene mutations cause abnormal or inadequate protein production, it can result in one of over 7,000 distinct types of rare and genetic diseases. About 80% of the estimated 400 million people worldwide with rare diseases are caused by a faulty gene, according to Global Genes.

As expression profiling helps with understanding diagnostics, and specific treatment options for chronic disorders, high demand will prevail in the long run as well. However, although preferred over conventional sequencing methods for its high sensitivity for gene expression, high throughput sequencing, and quantifiability, the high initial capital investment remains a substantial challenge facing more ubiquitous adoption of RNA sequencing.

Interest of Cancer Research Communities in RNA Sequencing Intact

The progresses that RNA sequencing method have exhibited over the past few decades gives strong indications about its significant application potential that has be leveraged over the foreseeable future. From bulk RNA sequencing to single-molecular, single-cell, and now till the spatial transcriptome, the approach has been revealing a high-resolution picture of individual cells with utmost accuracy. While cancers have remained a constant hot topic for researchers, RNA sequencing holds an impressive potential to aid in comprehending multiple facets in terms of both research, and therapeutics. It has already been in use within the area of oncology since the past decade to obtain invaluable insights into segments like cancer evolution, analysis of differential gene expression, biomarkers, and immunotherapy. Oncology drug resistance that has been the key obstacle responsible for the failure of cancer treatment could be potentially dealt with by using RNA sequencing technique as it presents an excellent means to aid in profound understanding of the cancer drug resistance mechanism. This would be a critical step towards the development of precision medicine for cancers, adding value to the future of cancer prevention, diagnosis, and treatment.

These are some of the recent developments on a similar line.

Liver cancer is currently one of the most common malignant tumours, and ranks among the top cancer-related mortality causes worldwide. A recently conducted study in July, 2021 suggests that RNA sequencing can be potentially beneficial for exploring new therapeutic avenues for liver cancer. The method supposedly promotes better understanding of the disease metabolism.
The fact that even the most treatable cancers can remain incurable in certain patients is painful. Relapsing cancers stay one of the leading causes of patients’ death, especially in case of paediatric patients. It is all about being able to understand if or not a patient will respond to a certain treatment. In July, 2021, a team of scientists at the US-based St Jude Children’s Hospital published some of the most clinically relevant, and highly insightful findings about how RNA sequencing in addition to whole exome sequencing can open doors to precision medicine application in paediatric cancer patients. If precision medicine is to be life-saving, RNA sequencing would be the one playing out an indispensable part of it here, as suggested by the study.

North America Continues to Favour Greater Adoption of RNA Sequencing Techniques for R&D

While North America has been the top performer in the global RNA sequencing market, the trend will most likely continue through the forecast period owing to the rising acceptance for RNA sequencing techniques. With the region witnessing a greater number of RNA sequencing grants, and improving reimbursement coverage for diagnostics, the market will continue to flourish in long term. The firming up of the field of personalised medicine, especially in the US, will further fortify the market performance here. Remarkably growing R&D investments in addition to robust external funding will also extend support to the expansion of market. All over the globe, several governments have been granting substantial funds to genomics research in the wake of dramatically rising prevalence of cancers, as well as rare diseases, the latter mostly being genetic/inherent.

Approximately 3-10% of all hospitalisations (regardless of the patient age) are related to a rare disease, whereas 65% of rare diseases are associated with reduced lifespan. The average time to get an accurate rare disease diagnosis is between six and eight years. According to Rare Diseases International, and EURORDIS, rare diseases currently affect at any point in time 3.5% - 5.9% of the worldwide population; 72% are genetic, of which around 70% start in childhood.

Major Participants in Global RNA Sequencing Market

Some of the most prominent players contributing towards promising growth prospects of the RNA sequencing market include Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann La-Roche AG, Merck KGaA., BGI, F. Fluidigm Corporation, Oxford Nanopore Technologies, Lexogen GmbH, Pacific Biosciences, Becton, Dickinson and Company, QIAGEN N.V., Dolomite Bio, Takara Bio Inc., PerkinElmer Inc., Eurofins Scientific, Tecan Genomics, Inc., GENEWIZ, Inc., Hamilton Company, Macrogen, and Zymo Research. QIAGEN N.V. had launched a range of novel RNA sequencing library preparation solutions for NGS in October, 2011. In June, 2017, a strategic agreement between Agilent Technologies, and Agendia was announced over the development of a version of the latter’s RNA sequencing kit for the former’s portfolio.

Regional Classification of the Global RNA Sequencing Market is Described Below:

North America

U.S.
Canada

Europe

Germany
France
Spain
U.K.
Italy
Russia
Rest of Europe

Asia Pacific

China
Japan
India
Southeast Asia
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East and Africa

GCC
South Africa
Rest of Middle East and Africa

*Regions and countries are subject to change based on data availability

Key Elements Included In The Study: Global RNA Sequencing Market

RNA Sequencing Market by Product/Technology/Grade, Application/End-user, and Region
Executive Summary (Opportunity Analysis and Key Trends)
Historical Market Size and Estimates, Value, 2018 - 2022
Market Value at Regional and Country Level, 2023 - 2030
Market Dynamics and Economic Overview
Market Size in Value, Growth Rates, and Forecast Figures, 2023 - 2030
Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies
Regional and Product/Grade/Application/End-user Price Trends Analysis
Value Chain and Five Force’s Analysis
Regional/Sub-region/Country Market Size and Trend Analysis
Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

The report will be prepared in a PPT format and will be delivered in a PDF format.

Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.

If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.

If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.

If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

1. Executive Summary
1.1. Global RNA Sequencing Market Outlook, 2018 - 2030 (US$ Million)
1.2. Global RNA Sequencing Market Incremental Opportunity, 2018 - 2030 (US$ Million)
1.3. Key Industry Trends

2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.1.1. Driver 1
  2.2.1.2. Driver 2
  2.2.2. Restraints
  2.2.2.1. Restraint 1
  2.2.2.2. Restraint 2
  2.2.3. Market Opportunities Matrix
2.3. Porters Five Forces Analysis
2.4. Regulatory Guidelines & Reimbursement Scenario
2.5. Covid-19 Impact Analysis

3. Pricing Analysis, 2022
3.1. Average Selling Price, by Key Regions

4. Global RNA Sequencing Market Outlook, 2018 - 2030
4.1. Global RNA Sequencing Market Outlook, by Product, Value (US$ Mn), 2018 - 2030
  4.1.1. Key Highlights
  4.1.1.1. Instruments
  4.1.1.2. Reagents & Kits
  4.1.1.3. Software
  4.1.2. BPS Analysis/Market Attractiveness Analysis
4.2. Global RNA Sequencing Market Outlook, by Technology, Value (US$ Mn), 2018 - 2030
  4.2.1. Key Highlights
  4.2.1.1. Sequencing by Synthesis
  4.2.1.2. Ion Semiconductor Sequencing
  4.2.1.3. Nanopore Sequencing
  4.2.1.4. Single Molecule-based Sequencing
  4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. Global RNA Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
  4.3.1. Key Highlights
  4.3.1.1. Diagnostics
  4.3.1.2. Personalized Medicine
  4.3.1.3. Drug Research & Development
  4.3.1.4. Biomarker Research
  4.3.1.5. Others
  4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. Global RNA Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  4.4.1. Key Highlights
  4.4.1.1. Pharmaceutical & Biotech Companies
  4.4.1.2. Diagnostic Centers
  4.4.1.3. Academic & Research Institutes
  4.4.1.4. Others
  4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. Global RNA Sequencing Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
  4.5.1. Key Highlights
  4.5.1.1. North America
  4.5.1.2. Europe
  4.5.1.3. Asia Pacific
  4.5.1.4. Rest of the World
  4.5.2. BPS Analysis/Market Attractiveness Analysis

5. North America RNA Sequencing Market Outlook, 2018 - 2030
5.1. North America RNA Sequencing Market Outlook, by Product, Value (US$ Mn), 2018 - 2030
  5.1.1. Key Highlights
  5.1.1.1. Instruments
  5.1.1.2. Reagents & Kits
  5.1.1.3. Software
  5.1.2. BPS Analysis/Market Attractiveness Analysis
5.2. North America RNA Sequencing Market Outlook, by Technology, Value (US$ Mn), 2018 - 2030
  5.2.1. Key Highlights
  5.2.1.1. Sequencing by Synthesis
  5.2.1.2. Ion Semiconductor Sequencing
  5.2.1.3. Nanopore Sequencing
  5.2.1.4. Single Molecule-based Sequencing
  5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America RNA Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
  5.3.1. Key Highlights
  5.3.1.1. Diagnostics
  5.3.1.2. Personalized Medicine
  5.3.1.3. Drug Research & Development
  5.3.1.4. Biomarker Research
  5.3.1.5. Others
  5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. North America RNA Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  5.4.1. Key Highlights
  5.4.1.1. Pharmaceutical & Biotech Companies
  5.4.1.2. Diagnostic Centers
  5.4.1.3. Academic & Research Institutes
  5.4.1.4. Others
  5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. North America RNA Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  5.5.1. Key Highlights
  5.5.1.1. U.S.
  5.5.1.2. Canada
  5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Europe RNA Sequencing Market Outlook, 2018 - 2030
6.1. Europe RNA Sequencing Market Outlook, by Product, Value (US$ Mn), 2018 - 2030
  6.1.1. Key Highlights
  6.1.1.1. Instruments
  6.1.1.2. Reagents & Kits
  6.1.1.3. Software
  6.1.2. BPS Analysis/Market Attractiveness Analysis
6.2. Europe RNA Sequencing Market Outlook, by Technology, Value (US$ Mn), 2018 - 2030
  6.2.1. Key Highlights
  6.2.1.1. Sequencing by Synthesis
  6.2.1.2. Ion Semiconductor Sequencing
  6.2.1.3. Nanopore Sequencing
  6.2.1.4. Single Molecule-based Sequencing
  6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe RNA Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
  6.3.1. Key Highlights
  6.3.1.1. Diagnostics
  6.3.1.2. Personalized Medicine
  6.3.1.3. Drug Research & Development
  6.3.1.4. Biomarker Research
  6.3.1.5. Others
  6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Europe RNA Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  6.4.1. Key Highlights
  6.4.1.1. Pharmaceutical & Biotech Companies
  6.4.1.2. Diagnostic Centers
  6.4.1.3. Academic & Research Institutes
  6.4.1.4. Others
  6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Europe RNA Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  6.5.1. Key Highlights
  6.5.1.1. Germany
  6.5.1.2. France
  6.5.1.3. U.K.
  6.5.1.4. Italy
  6.5.1.5. Spain
  6.5.1.6. Rest of Europe
  6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Asia Pacific RNA Sequencing Market Outlook, 2018 - 2030
7.1. Asia Pacific RNA Sequencing Market Outlook, by Product, Value (US$ Mn), 2018 - 2030
  7.1.1. Key Highlights
  7.1.1.1. Instruments
  7.1.1.2. Reagents & Kits
  7.1.1.3. Software
  7.1.2. BPS Analysis/Market Attractiveness Analysis
7.2. Asia Pacific RNA Sequencing Market Outlook, by Technology, Value (US$ Mn), 2018 - 2030
  7.2.1. Key Highlights
  7.2.1.1. Sequencing by Synthesis
  7.2.1.2. Ion Semiconductor Sequencing
  7.2.1.3. Nanopore Sequencing
  7.2.1.4. Single Molecule-based Sequencing
  7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific RNA Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
  7.3.1. Key Highlights
  7.3.1.1. Diagnostics
  7.3.1.2. Personalized Medicine
  7.3.1.3. Drug Research & Development
  7.3.1.4. Biomarker Research
  7.3.1.5. Others
  7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Asia Pacific RNA Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  7.4.1. Key Highlights
  7.4.1.1. Pharmaceutical & Biotech Companies
  7.4.1.2. Diagnostic Centers
  7.4.1.3. Academic & Research Institutes
  7.4.1.4. Others
  7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Asia Pacific RNA Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  7.5.1. Key Highlights
  7.5.1.1. China
  7.5.1.2. Japan
  7.5.1.3. India
  7.5.1.4. South Korea
  7.5.1.5. Australia & New Zealand
  7.5.1.6. Rest of Asia Pacific
  7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Rest of the World RNA Sequencing Market Outlook, 2018 - 2030
8.1. Rest of the World RNA Sequencing Market Outlook, by Product, Value (US$ Mn), 2018 - 2030
  8.1.1. Key Highlights
  8.1.1.1. Instruments
  8.1.1.2. Reagents & Kits
  8.1.1.3. Software
  8.1.2. BPS Analysis/Market Attractiveness Analysis
8.2. Rest of the World RNA Sequencing Market Outlook, by Technology, Value (US$ Mn), 2018 - 2030
  8.2.1. Key Highlights
  8.2.1.1. Sequencing by Synthesis
  8.2.1.2. Ion Semiconductor Sequencing
  8.2.1.3. Nanopore Sequencing
  8.2.1.4. Single Molecule-based Sequencing
  8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Rest of the World RNA Sequencing Market Outlook, by Application, Value (US$ Mn), 2018 - 2030
  8.3.1. Key Highlights
  8.3.1.1. Diagnostics
  8.3.1.2. Personalized Medicine
  8.3.1.3. Drug Research & Development
  8.3.1.4. Biomarker Research
  8.3.1.5. Others
  8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Rest of the World RNA Sequencing Market Outlook, by End User, Value (US$ Mn), 2018 - 2030
  8.4.1. Key Highlights
  8.4.1.1. Pharmaceutical & Biotech Companies
  8.4.1.2. Diagnostic Centers
  8.4.1.3. Academic & Research Institutes
  8.4.1.4. Others
  8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Rest of the World RNA Sequencing Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
  8.5.1. Key Highlights
  8.5.1.1. Latin America
  8.5.1.2. Middle East & Africa
  8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape
9.1. Company Market Share Analysis
9.2. Company Profiles
  9.2.1. Agilent Technologies
  9.2.1.1. Company Overview
  9.2.1.2. Financial Overview
  9.2.1.3. Product Portfolio
  9.2.1.4. Recent Developments
*Above details will include, but not be limited to below list of companies based on availability
  9.2.2. PerkinElmer, Inc.
  9.2.3. Thermo Fischer Scientific
  9.2.4. Bio-Rad Laboratories
  9.2.5. Illumina, Inc.
  9.2.6. Takara Bio
  9.2.7. CD Genomics
  9.2.8. Oxford Nanopore TechnologiesOthers

10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

RNA Sequencing Market

Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Request Table of Contents

Latest Reports

Our Research Methodology